Tengfei Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tengfei Guo has a total of 513 co-authors. Here are the top co-authors by number of shared publications:
Anqi Li
32 shared publicationsYue Cai
30 shared publicationsGuoyu Lan
26 shared publicationsPan Sun
25 shared publicationsZhengbo He
22 shared publicationsJie Yang
21 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Springer Nature in Molecular Neurodegeneration
Revealing white matter hyperintensities-related faster posterior cortical tau accumulation in Alzheimer’s Disease
Background: Alzheimer’s disease (AD) is a multifactorial disorder in which cerebrovascular abnormalities frequently co-occur with β-amyloid (Aβ) and tau pathology. White matter hyperintensities (WMH), a common marker of cerebral small vessel disease, are associated with cognitive impairment and are highly prevalent across the AD continuum. However, the extent to which WMH burden is associated with spatial patterns of tau pathology and its longitudinal accumulation remains unclear. Methods: We examined 1,455 participants with Aβ PET, tau PET, T2-FLAIR MRI, and cognitive assessments from four independent cohorts: ADNI ( n = 710), A4/LEARN ( n = 440), GHABS ( n = 249), and PREVENT-AD ( n = 56). Resting-state functional MRI data were available in subsets of ADNI and A4, and CSF SomaScan proteomic data were available in ADNI and PREVENT-AD. Associations of WMH burden with longitudinal tau accumulation and network-based tau propagation were examined. A data-driven approach was used to identify distinct tau subtypes. WMH burden, tau accumulation, and clinical and biological characteristics were evaluated across subtypes. Results: Greater total WMH burden was associated with faster tau accumulation (ADNI, A4) or higher subsequent tau burden (GHABS) in the temporal meta-ROI among Aβ-positive (A+) individuals. These associations were attenuated after accounting for Aβ burden. However, greater WMH burden, particularly in the occipital lobe, remained significantly associated with faster tau accumulation and network-based tau propagation in occipital regions after adjustment for Aβ burden. An occipital-dominant tau subtype was identified, characterized by greater occipital than parietal tau burden. This subtype showed more widespread associations between WMH and tau accumulation, an older estimated age of Aβ positivity onset, and a higher prevalence of hypertension, together with slower global tau accumulation and cognitive decline than the parietal-dominant subtype. CSF proteomic analyses further identified vascular and extracellular matrix pathways related to tenascin-C (TNC) in the occipital-dominant subtype. Conclusions: Greater WMH burden was associated with faster tau accumulation and network-based tau propagation, with the most consistent associations involving occipital regions. These findings suggest that the association between WMH burden and occipital tau progression may reflect vascular contributions to regional tau vulnerability in the context of AD pathology.
- 11 November 2026
- Published by Springer Nature in Molecular Neurodegeneration
Open AccessRevealing white matter hyperintensities-related faster posterior cortical tau accumulation in Alzheimer’s Disease
Background: Alzheimer’s disease (AD) is a multifactorial disorder in which cerebrovascular abnormalities frequently co-occur with β-amyloid (Aβ) and tau pathology. White matter hyperintensities (WMH), a common marker of cerebral small vessel disease, are associated with cognitive impairment and are highly prevalent across the AD continuum. However, the extent to which WMH burden is associated with spatial patterns of tau pathology and its longitudinal accumulation remains unclear. Methods: We examined 1,455 participants with Aβ PET, tau PET, T2-FLAIR MRI, and cognitive assessments from four independent cohorts: ADNI ( n = 710), A4/LEARN ( n = 440), GHABS ( n = 249), and PREVENT-AD ( n = 56). Resting-state functional MRI data were available in subsets of ADNI and A4, and CSF SomaScan proteomic data were available in ADNI and PREVENT-AD. Associations of WMH burden with longitudinal tau accumulation and network-based tau propagation were examined. A data-driven approach was used to identify distinct tau subtypes. WMH burden, tau accumulation, and clinical and biological characteristics were evaluated across subtypes. Results: Greater total WMH burden was associated with faster tau accumulation (ADNI, A4) or higher subsequent tau burden (GHABS) in the temporal meta-ROI among Aβ-positive (A+) individuals. These associations were attenuated after accounting for Aβ burden. However, greater WMH burden, particularly in the occipital lobe, remained significantly associated with faster tau accumulation and network-based tau propagation in occipital regions after adjustment for Aβ burden. An occipital-dominant tau subtype was identified, characterized by greater occipital than parietal tau burden. This subtype showed more widespread associations between WMH and tau accumulation, an older estimated age of Aβ positivity onset, and a higher prevalence of hypertension, together with slower global tau accumulation and cognitive decline than the parietal-dominant subtype. CSF proteomic analyses further identified vascular and extracellular matrix pathways related to tenascin-C (TNC) in the occipital-dominant subtype. Conclusions: Greater WMH burden was associated with faster tau accumulation and network-based tau propagation, with the most consistent associations involving occipital regions. These findings suggest that the association between WMH burden and occipital tau progression may reflect vascular contributions to regional tau vulnerability in the context of AD pathology.
- 9 September 2026
- Published by Elsevier in The Lancet Neurology
- Vol. 25 (10) , 879-880
Charting the future of biomarkers and therapy in Alzheimer's disease
- 9 September 2026
- Published by Elsevier in The Lancet Neurology
- Vol. 25 (10) , 879-880
Charting the future of biomarkers and therapy in Alzheimer's disease
- Open Access
- 30 August 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (9) , e71783
Longitudinal plasma phosphorylated tau217 classification and the association with Alzheimer's disease progression
INTRODUCTION: Longitudinal diagnostic and prognostic validity of plasma phosphorylated tau217 (p‐tau217) in Alzheimer's disease (AD) remains uncertain. METHODS: In this multi‐cohort study of 2117 individuals, we established baseline plasma p‐tau217 thresholds for amyloid‐β–positron emission tomography (Aβ‐PET) and assessed their longitudinal classification stability and prognostic relevance for AD‐related outcomes. RESULTS: Baseline‐defined cutoffs achieved high and sustained accuracy (86%–95%) for Aβ‐PET positivity over up to 5 years of follow‐up. Longitudinally, most p‐tau217–positive individuals remained stable (93%–98%), whereas the intermediate zone group progressed more to positive (44%–78%) than p‐tau217–negative individuals (4%–21%). Participants with stable‐positive and progress‐to‐positive p‐tau217 profiles more frequently exhibited Aβ abnormalities (90%–100% and 64%–96%, respectively) and experienced accelerated tau accumulation, hippocampal atrophy, and incident dementia compared to those with a stable‐negative p‐tau217 profile. DISCUSSION: These findings support the high stability and Aβ‐PET classification performance of longitudinal plasma p‐tau217 monitoring in AD, providing a scalable tool for risk stratification and disease monitoring.
- 30 August 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (9) , e71783
Open AccessLongitudinal plasma phosphorylated tau217 classification and the association with Alzheimer's disease progression
INTRODUCTION: Longitudinal diagnostic and prognostic validity of plasma phosphorylated tau217 (p‐tau217) in Alzheimer's disease (AD) remains uncertain. METHODS: In this multi‐cohort study of 2117 individuals, we established baseline plasma p‐tau217 thresholds for amyloid‐β–positron emission tomography (Aβ‐PET) and assessed their longitudinal classification stability and prognostic relevance for AD‐related outcomes. RESULTS: Baseline‐defined cutoffs achieved high and sustained accuracy (86%–95%) for Aβ‐PET positivity over up to 5 years of follow‐up. Longitudinally, most p‐tau217–positive individuals remained stable (93%–98%), whereas the intermediate zone group progressed more to positive (44%–78%) than p‐tau217–negative individuals (4%–21%). Participants with stable‐positive and progress‐to‐positive p‐tau217 profiles more frequently exhibited Aβ abnormalities (90%–100% and 64%–96%, respectively) and experienced accelerated tau accumulation, hippocampal atrophy, and incident dementia compared to those with a stable‐negative p‐tau217 profile. DISCUSSION: These findings support the high stability and Aβ‐PET classification performance of longitudinal plasma p‐tau217 monitoring in AD, providing a scalable tool for risk stratification and disease monitoring.
- 14 August 2026
- Published by Wiley in Annals of Neurology
- Vol. 100 (5) , 998-1011
Cross‐Sectional and Longitudinal Diagnostic Performance of Plasma p‐tau217 and p‐tau217/Aβ42 in Alzheimer's Disease
Objective: Recent studies suggest that combining plasma phosphorylated tau (p‐tau) with β ‐amyloid (A β ) may improve diagnosis accuracy for Alzheimer's disease (AD). However, the cross‐sectional and longitudinal concordance of these markers with A β positron emission tomography (PET) positivity remains incompletely understood. This study aimed to evaluate the diagnostic performance of plasma p‐tau, alone and in combination with plasma A β , in AD. Methods: We included 326 participants from the Alzheimer's Disease Neuroimaging Initiative and 357 Chinese older adults from the Greater‐Bay‐Area Healthy Aging Brain Study who underwent A β ‐PET imaging. Longitudinal data were available for 285 Alzheimer's Disease Neuroimaging Initiative participants. Plasma p‐tau181, p‐tau217, A β 42, and A β 40 were measured on different analytical platforms. Diagnostic performance for A β ‐PET positivity was assessed using a two‐cutoff approach. Results: Combining plasma p‐tau with A β 42 or the A β 42/40 ratio reduced the intermediate zone. Notably, p‐tau217/A β 42 showed stronger agreement with A β ‐PET positivity than p‐tau217 alone. Among individuals classified as p‐tau217/A β 42 positive but p‐tau217 intermediate, 57.1 to 83.3% were A β ‐PET positive. Longitudinally, most Stable Positive (88.0–96.1%) and Stable Negative (89.4–90.9%) cases defined by p‐tau217 or p‐tau217/A β 42 were A β ‐PET positive and A β ‐PET negative, respectively. Critically, 69.7 to 75.8% of Non‐positive to Positive cases defined by p‐tau217/A β 42 were A β ‐PET positive. Interpretation: These findings provide novel insights into the cross‐sectional and longitudinal diagnostic performance of plasma p‐tau217/A β 42 in AD. To be specific, plasma p‐tau217/A β 42 can reduce the intermediate zone and improve agreement with A β ‐PET positivity, and longitudinal p‐tau217/A β 42 monitoring is particularly informative for identifying A β ‐PET–positive patients who were p‐tau217/A β 42 negative or intermediate at baseline and were misclassified as low risk of AD. ANN NEUROL 2026;100:998–1011
- 14 August 2026
- Published by Wiley in Annals of Neurology
- Vol. 100 (5) , 998-1011
Cross‐Sectional and Longitudinal Diagnostic Performance of Plasma p‐tau217 and p‐tau217/Aβ42 in Alzheimer's Disease
Objective: Recent studies suggest that combining plasma phosphorylated tau (p‐tau) with β ‐amyloid (A β ) may improve diagnosis accuracy for Alzheimer's disease (AD). However, the cross‐sectional and longitudinal concordance of these markers with A β positron emission tomography (PET) positivity remains incompletely understood. This study aimed to evaluate the diagnostic performance of plasma p‐tau, alone and in combination with plasma A β , in AD. Methods: We included 326 participants from the Alzheimer's Disease Neuroimaging Initiative and 357 Chinese older adults from the Greater‐Bay‐Area Healthy Aging Brain Study who underwent A β ‐PET imaging. Longitudinal data were available for 285 Alzheimer's Disease Neuroimaging Initiative participants. Plasma p‐tau181, p‐tau217, A β 42, and A β 40 were measured on different analytical platforms. Diagnostic performance for A β ‐PET positivity was assessed using a two‐cutoff approach. Results: Combining plasma p‐tau with A β 42 or the A β 42/40 ratio reduced the intermediate zone. Notably, p‐tau217/A β 42 showed stronger agreement with A β ‐PET positivity than p‐tau217 alone. Among individuals classified as p‐tau217/A β 42 positive but p‐tau217 intermediate, 57.1 to 83.3% were A β ‐PET positive. Longitudinally, most Stable Positive (88.0–96.1%) and Stable Negative (89.4–90.9%) cases defined by p‐tau217 or p‐tau217/A β 42 were A β ‐PET positive and A β ‐PET negative, respectively. Critically, 69.7 to 75.8% of Non‐positive to Positive cases defined by p‐tau217/A β 42 were A β ‐PET positive. Interpretation: These findings provide novel insights into the cross‐sectional and longitudinal diagnostic performance of plasma p‐tau217/A β 42 in AD. To be specific, plasma p‐tau217/A β 42 can reduce the intermediate zone and improve agreement with A β ‐PET positivity, and longitudinal p‐tau217/A β 42 monitoring is particularly informative for identifying A β ‐PET–positive patients who were p‐tau217/A β 42 negative or intermediate at baseline and were misclassified as low risk of AD. ANN NEUROL 2026;100:998–1011
- Open Access
- 6 August 2026
- Published by Elsevier in SSRN Electronic Journal
Habitual Walking Associated with Slower Cognitive Decline in Preclinical Alzheimer’s: Subgroup Benefits and WMH-Mediation Findings
Background: Although physical activity benefits cognition, the efficacy, priority subpopulations, and underlying pathways of habitual walking in preclinical Alzheimer’s disease (AD) remain elusive.Methods: We examined how weekly walking duration (360min/week) affects cognitive and functional change in 484 β-amyloid (Aβ)-negative and 535 Aβ-positive cognitively unimpaired (CU) older adults. Linear mixed models were utilized to assess the walking-cognition association, effect modification by biological profiles (age, sex, genetic risk, AD pathology), and the mediating role of WMH.Findings: In preclinical AD, longer walking was related to slower cognitive and functional decline, whereas Aβ-negative individuals benefited only in episodic memory. Preclinical AD individuals with younger ages (<75 years), females, APOE ε4 carriers, and higher baseline AD pathology showed more benefit. Slower WMH progression partially mediated the walking-related cognitive benefits.Interpretation: Active walking associated with slower cognitive and functional decline in preclinical AD, with benefits pronounced in specific subgroups and partially mediated by slower WMH progression.
- 6 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessHabitual Walking Associated with Slower Cognitive Decline in Preclinical Alzheimer’s: Subgroup Benefits and WMH-Mediation Findings
Background: Although physical activity benefits cognition, the efficacy, priority subpopulations, and underlying pathways of habitual walking in preclinical Alzheimer’s disease (AD) remain elusive.Methods: We examined how weekly walking duration (360min/week) affects cognitive and functional change in 484 β-amyloid (Aβ)-negative and 535 Aβ-positive cognitively unimpaired (CU) older adults. Linear mixed models were utilized to assess the walking-cognition association, effect modification by biological profiles (age, sex, genetic risk, AD pathology), and the mediating role of WMH.Findings: In preclinical AD, longer walking was related to slower cognitive and functional decline, whereas Aβ-negative individuals benefited only in episodic memory. Preclinical AD individuals with younger ages (<75 years), females, APOE ε4 carriers, and higher baseline AD pathology showed more benefit. Slower WMH progression partially mediated the walking-related cognitive benefits.Interpretation: Active walking associated with slower cognitive and functional decline in preclinical AD, with benefits pronounced in specific subgroups and partially mediated by slower WMH progression.
- Open Access
- 9 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (6) , e71574
“Digital eye tracking and plasma biomarkers: Distinguishing functional cognitive impairment from Alzheimer's disease biology”
- 9 June 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (6) , e71574
Open Access“Digital eye tracking and plasma biomarkers: Distinguishing functional cognitive impairment from Alzheimer's disease biology”
- Open Access
- 22 May 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (5) , e70618
Diagnostic and Prognostic Utility of Plasma p‐tau217 for Alzheimer's Disease in Chinese Elderly: Insights From the SILCODE Study With a Derived Threshold
Background: Plasma phosphorylated tau 217 (p‐tau217) has emerged as a promising Alzheimer's disease (AD) biomarker, yet its longitudinal associations with neurodegeneration and cognitive decline remain inadequately characterized in Chinese populations, and ethnicity‐specific diagnostic thresholds are lacking for optimal clinical application. Methods: A total of 541 participants (402 cognitively unimpaired [CU]; 139 cognitively impaired [CI]) from the Sino Longitudinal Study on Cognitive Decline (SILCODE) cohort were enrolled. Cross‐sectional and longitudinal associations of plasma p‐tau217 with amyloid‐β (Aβ) pathology, neurodegeneration, and cognition were evaluated. Diagnostic thresholds were derived using receiver operating characteristic analysis, and Cox regression assessed prognostic value for clinical progression. Results: Cross‐sectionally, baseline p‐tau217 was associated with greater Aβ burden, neurodegeneration, and poorer cognition in the whole cohort and CI group; in the CU group, associations were confined to amyloid measures. Longitudinally, accelerated p‐tau217 accumulation was associated with faster neurodegeneration and cognitive decline in the whole cohort, with stage‐dependent patterns: nominal associations with neurodegenerative markers in CU and prominent cognitive associations in CI. Plasma p‐tau217 demonstrated high diagnostic accuracy for amyloid positivity (AUC = 0.891; cutoff: 0.529 pg/mL). Threshold‐based stratification effectively differentiated individuals by Aβ burden, neurodegeneration, and cognitive trajectories. Elevated baseline p‐tau217 predicted higher progression risk (Whole cohort: HR = 2.66 [1.28–5.53], p = 0.009; CU: HR = 2.44 [1.07–5.59], p = 0.034). Conclusion: Plasma p‐tau217 serves as a valuable diagnostic and prognostic biomarker for AD, even among CU individuals, and the ethnicity‐specific threshold of 0.529 pg/mL enhances its clinical applicability for early detection and risk stratification in Chinese populations.
- 22 May 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (5) , e70618
Open AccessDiagnostic and Prognostic Utility of Plasma p‐tau217 for Alzheimer's Disease in Chinese Elderly: Insights From the SILCODE Study With a Derived Threshold
Background: Plasma phosphorylated tau 217 (p‐tau217) has emerged as a promising Alzheimer's disease (AD) biomarker, yet its longitudinal associations with neurodegeneration and cognitive decline remain inadequately characterized in Chinese populations, and ethnicity‐specific diagnostic thresholds are lacking for optimal clinical application. Methods: A total of 541 participants (402 cognitively unimpaired [CU]; 139 cognitively impaired [CI]) from the Sino Longitudinal Study on Cognitive Decline (SILCODE) cohort were enrolled. Cross‐sectional and longitudinal associations of plasma p‐tau217 with amyloid‐β (Aβ) pathology, neurodegeneration, and cognition were evaluated. Diagnostic thresholds were derived using receiver operating characteristic analysis, and Cox regression assessed prognostic value for clinical progression. Results: Cross‐sectionally, baseline p‐tau217 was associated with greater Aβ burden, neurodegeneration, and poorer cognition in the whole cohort and CI group; in the CU group, associations were confined to amyloid measures. Longitudinally, accelerated p‐tau217 accumulation was associated with faster neurodegeneration and cognitive decline in the whole cohort, with stage‐dependent patterns: nominal associations with neurodegenerative markers in CU and prominent cognitive associations in CI. Plasma p‐tau217 demonstrated high diagnostic accuracy for amyloid positivity (AUC = 0.891; cutoff: 0.529 pg/mL). Threshold‐based stratification effectively differentiated individuals by Aβ burden, neurodegeneration, and cognitive trajectories. Elevated baseline p‐tau217 predicted higher progression risk (Whole cohort: HR = 2.66 [1.28–5.53], p = 0.009; CU: HR = 2.44 [1.07–5.59], p = 0.034). Conclusion: Plasma p‐tau217 serves as a valuable diagnostic and prognostic biomarker for AD, even among CU individuals, and the ethnicity‐specific threshold of 0.529 pg/mL enhances its clinical applicability for early detection and risk stratification in Chinese populations.
- Open Access
- 17 April 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (4) , e71397
Elevated plasma klotho levels attenuate Alzheimer's disease pathologies and cognitive decline in APOE ε4 carriers
INTRODUCTION: Klotho is a longevity‐associated protein with established neuroprotective properties. However, it is unclear how plasma klotho levels relate to Alzheimer's disease (AD) pathologies and cognitive performance. METHODS: In this study, we examined the associations between plasma klotho levels and plasma biomarkers, as well as amyloid beta (Aβ) positron emission tomography (PET), tau PET, neurodegeneration, and cognition, in 354 older adults. Stratified association, interaction, and mediation analyses were conducted to elucidate apolipoprotein E ( APOE ) ε4–dependent relationships and potential underlying pathways. RESULTS: Higher plasma klotho levels were associated with lower AD‐related biomarkers and cognitive decline in APOE ε4 carriers. Plasma klotho and APOE ε4 exhibited significant or marginal interactions with less abnormal changes in plasma phosphorylated tau217, glial fibrillary acidic protein, neurofilament light chain, Aβ PET, and cognition. These AD‐related biomarkers mediated the protective effect of plasma klotho on cognitive function in APOE ε4 carriers. DISCUSSION: This study suggests that plasma klotho is an APOE ε4–dependent protective factor, which may attenuate AD‐related pathology and improve cognitive performance.
- 17 April 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (4) , e71397
Open AccessElevated plasma klotho levels attenuate Alzheimer's disease pathologies and cognitive decline in APOE ε4 carriers
INTRODUCTION: Klotho is a longevity‐associated protein with established neuroprotective properties. However, it is unclear how plasma klotho levels relate to Alzheimer's disease (AD) pathologies and cognitive performance. METHODS: In this study, we examined the associations between plasma klotho levels and plasma biomarkers, as well as amyloid beta (Aβ) positron emission tomography (PET), tau PET, neurodegeneration, and cognition, in 354 older adults. Stratified association, interaction, and mediation analyses were conducted to elucidate apolipoprotein E ( APOE ) ε4–dependent relationships and potential underlying pathways. RESULTS: Higher plasma klotho levels were associated with lower AD‐related biomarkers and cognitive decline in APOE ε4 carriers. Plasma klotho and APOE ε4 exhibited significant or marginal interactions with less abnormal changes in plasma phosphorylated tau217, glial fibrillary acidic protein, neurofilament light chain, Aβ PET, and cognition. These AD‐related biomarkers mediated the protective effect of plasma klotho on cognitive function in APOE ε4 carriers. DISCUSSION: This study suggests that plasma klotho is an APOE ε4–dependent protective factor, which may attenuate AD‐related pathology and improve cognitive performance.
- 3 April 2026
- Published by Elsevier in Neurobiology of Aging
- Vol. 164, 19-27
Association of plasma glial fibrillary acidic protein and APOE-ε4 with Alzheimer’s disease
- 3 April 2026
- Published by Elsevier in Neurobiology of Aging
- Vol. 164, 19-27
Association of plasma glial fibrillary acidic protein and APOE-ε4 with Alzheimer’s disease
- Open Access
- 8 March 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (3) , e71253
A novel eye‐tracking digital marker outperforms plasma biomarkers in detecting cognitive impairment
INTRODUCTION: Detecting and monitoring cognitive performance in older adults is critical. In this study, we evaluated the validity of an eye‐tracking tool in diagnosing cognitive impairment. METHODS: We recruited 119 cognitively unimpaired (CU) individuals and 157 cognitively impaired (CI) patients who completed digital eye‐tracking tests and cognitive scales. Of them, 154, 120, 53, and 146 underwent plasma biomarker tests, amyloid‐β positron emission tomography (Aβ‐PET) scans, tau‐PET scans, and magnetic resonance imaging (MRI) scans. The diagnostic performance of eye‐tracking markers and their relationships to Alzheimer's disease biomarkers and cognition were examined. RESULTS: The eye‐tracking panel exhibited better performance (area under the curve [AUC] = 0.865) in classifying CI from CU compared to plasma Aβ 42/40 (AUC = 0.699), p‐Tau 217 (AUC = 0.769), p‐Tau 217 /Aβ 42 (AUC = 0.801), glial fibrillary acidic protein (GFAP; AUC = 0.804), and neurofilament light chain (NfL) (AUC = 0.826). DISCUSSION: These findings demonstrate the validity of digital eye‐tracking markers for screening patients with cognitive impairment, providing a novel digital marker for detecting cognitive decline in older adults.
- 8 March 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (3) , e71253
Open AccessA novel eye‐tracking digital marker outperforms plasma biomarkers in detecting cognitive impairment
INTRODUCTION: Detecting and monitoring cognitive performance in older adults is critical. In this study, we evaluated the validity of an eye‐tracking tool in diagnosing cognitive impairment. METHODS: We recruited 119 cognitively unimpaired (CU) individuals and 157 cognitively impaired (CI) patients who completed digital eye‐tracking tests and cognitive scales. Of them, 154, 120, 53, and 146 underwent plasma biomarker tests, amyloid‐β positron emission tomography (Aβ‐PET) scans, tau‐PET scans, and magnetic resonance imaging (MRI) scans. The diagnostic performance of eye‐tracking markers and their relationships to Alzheimer's disease biomarkers and cognition were examined. RESULTS: The eye‐tracking panel exhibited better performance (area under the curve [AUC] = 0.865) in classifying CI from CU compared to plasma Aβ 42/40 (AUC = 0.699), p‐Tau 217 (AUC = 0.769), p‐Tau 217 /Aβ 42 (AUC = 0.801), glial fibrillary acidic protein (GFAP; AUC = 0.804), and neurofilament light chain (NfL) (AUC = 0.826). DISCUSSION: These findings demonstrate the validity of digital eye‐tracking markers for screening patients with cognitive impairment, providing a novel digital marker for detecting cognitive decline in older adults.